Sectors & IndustriesHealthcareMedical Instruments & Supplies

Best Medical Stocks to Buy Now (2026)

Top medical stocks in 2026 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best medical stocks to buy now. Learn More.

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best medical stocks to buy right now are:

Infusystem Holdings (NYSEMKT:INFU) is the #1 top medical stock out of 54 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Infusystem Holdings (NYSEMKT:INFU) is: Value: C, Growth: C, Momentum: C, Sentiment: A, Safety: B, Financials: A, and AI: B.

Infusystem Holdings (NYSEMKT:INFU) has a Due Diligence Score of 38, which is 8 points higher than the medical industry average of 30.

INFU passed 12 out of 33 due diligence checks and has average fundamentals. Infusystem Holdings has seen its stock return 52.18% over the past year, overperforming other medical stocks by 57 percentage points.

Infusystem Holdings has an average 1 year price target of $15.00, an upside of 59.24% from Infusystem Holdings's current stock price of $9.42.

Infusystem Holdings stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 1 analyst covering Infusystem Holdings, 100% have issued a Strong Buy rating, 0% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Sanara Medtech (NASDAQ:SMTI) is the #2 top medical stock out of 54 with a Zen Rating of B. Stocks with a rating of B have had an average return of +19.88% per year. Learn more.

The Component Grade breakdown for Sanara Medtech (NASDAQ:SMTI) is: Value: C, Growth: A, Momentum: C, Sentiment: B, Safety: C, Financials: C, and AI: C.

Sanara Medtech (NASDAQ:SMTI) has a Due Diligence Score of 18, which is -12 points lower than the medical industry average of 30. Although this number is below the industry average, our proven quant model rates SMTI as a "B".

SMTI passed 6 out of 33 due diligence checks and has weak fundamentals. Sanara Medtech has seen its stock lose -20.28% over the past year, underperforming other medical stocks by -15 percentage points.

Sanara Medtech has an average 1 year price target of $34.33, an upside of 55.92% from Sanara Medtech's current stock price of $22.02.

Sanara Medtech stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 3 analysts covering Sanara Medtech, 66.67% have issued a Strong Buy rating, 33.33% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Bausch & Lomb (NYSE:BLCO) is the #3 top medical stock out of 54 with a Zen Rating of B. Stocks with a rating of B have had an average return of +19.88% per year. Learn more.

The Component Grade breakdown for Bausch & Lomb (NYSE:BLCO) is: Value: B, Growth: A, Momentum: C, Sentiment: B, Safety: C, Financials: C, and AI: C.

Bausch & Lomb (NYSE:BLCO) has a Due Diligence Score of 16, which is -14 points lower than the medical industry average of 30. Although this number is below the industry average, our proven quant model rates BLCO as a "B".

BLCO passed 5 out of 33 due diligence checks and has weak fundamentals. Bausch & Lomb has seen its stock return 28.74% over the past year, overperforming other medical stocks by 34 percentage points.

Bausch & Lomb has an average 1 year price target of $18.50, an upside of 24.41% from Bausch & Lomb's current stock price of $14.87.

Bausch & Lomb stock has a consensus Buy recommendation according to Wall Street analysts. Of the 6 analysts covering Bausch & Lomb, 16.67% have issued a Strong Buy rating, 16.67% have issued a Buy, 66.67% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Out of 11 medical stocks that have issued dividends in the past year, the 3 medical stocks with the highest dividend yields are:

Embecta (NASDAQ:EMBC) has an annual dividend yield of 14.79%, which is 12 percentage points higher than the medical industry average of 2.63%.

Embecta's dividend payout ratio of 31.2% indicates that its high dividend yield is sustainable for the long-term.

Becton Dickinson & Co (NYSE:BDX) has an annual dividend yield of 2.91%, which is the same as the medical industry average of 2.63%. Becton Dickinson & Co's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Becton Dickinson & Co's dividend has shown consistent growth over the last 10 years.

Becton Dickinson & Co's dividend payout ratio of 105.8% indicates that its dividend yield might not be sustainable for the long-term.

Utah Medical Products (NASDAQ:UTMD) has an annual dividend yield of 1.84%, which is -1 percentage points lower than the medical industry average of 2.63%. Utah Medical Products's dividend payout is not stable, having dropped more than 10% one times in the last 10 years. Utah Medical Products's dividend has shown consistent growth over the last 10 years.

Utah Medical Products's dividend payout ratio of 36.4% indicates that its dividend yield is sustainable for the long-term.

Medical stocks were up 1.53% in the last day, and down -0.9% over the last week.

We couldn't find a catalyst for why medical stocks are up.

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued medical stocks right now are:

Embecta (NASDAQ:EMBC) is the most undervalued medical stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Embecta has a valuation score of 43, which is 25 points higher than the medical industry average of 18. It passed 3 out of 7 valuation due diligence checks.

Embecta's stock has dropped -68.07% in the past year. It has underperformed other stocks in the medical industry by -63 percentage points.

Becton Dickinson & Co (NYSE:BDX) is the second most undervalued medical stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Becton Dickinson & Co has a valuation score of 43, which is 25 points higher than the medical industry average of 18. It passed 3 out of 7 valuation due diligence checks.

Becton Dickinson & Co's stock has dropped -14.6% in the past year. It has underperformed other stocks in the medical industry by -9 percentage points.

Resmed (NYSE:RMD) is the third most undervalued medical stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Resmed has a valuation score of 14, which is -4 points higher than the medical industry average of 18. It passed 1 out of 7 valuation due diligence checks. Although this number is below the industry average, our proven quant model rates RMD a Valuation Rating of "B".

Resmed's stock has dropped -24.81% in the past year. It has underperformed other stocks in the medical industry by -20 percentage points.

50% of medical stocks rated by analysts are a strong buy right now. On average, analysts expect medical stocks to rise by 28.81% over the next year.

2.38% of medical stocks have a Zen Rating of A (Strong Buy), 30.95% of medical stocks are rated B (Buy), 52.38% are rated C (Hold), 14.29% are rated D (Sell), and 0% are rated F (Strong Sell).